Last update 21 Nov 2024

cH8/1N1 LAIV(PATH)

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms-
Target-
Mechanism
Immunostimulants
Therapeutic Areas
Infectious DiseasesRespiratory Diseases
Active Indication-
Inactive Indication
Influenza, Human
Originator Organization
Program for Appropriate Technology in HealthProgram for Appropriate Technology in Health
Active Organization-
Inactive Organization
Program for Appropriate Technology in HealthProgram for Appropriate Technology in HealthGSK PlcGSK PlcThe Emmes Co. LLCThe Emmes Co. LLC
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with cH8/1N1 LAIV(PATH)
NCT03300050 / CompletedPhase 1IIT
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
100 Clinical Results associated with cH8/1N1 LAIV(PATH)
Login to view more data
100 Translational Medicine associated with cH8/1N1 LAIV(PATH)
Login to view more data
100 Patents (Medical) associated with cH8/1N1 LAIV(PATH)
Login to view more data
100 Deals associated with cH8/1N1 LAIV(PATH)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 1
US
Program for Appropriate Technology in HealthProgram for Appropriate Technology in Health
10 Oct 2017
Influenza, HumanPhase 1
US
GSK PlcGSK Plc
10 Oct 2017
Influenza, HumanPhase 1
US
The Emmes Co. LLCThe Emmes Co. LLC
10 Oct 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03300050 (CTgov)
Phase 1
Influenza, Human
65
(Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + Adjuvant)
zmechujyxm(tbhdaeirss) = rhbeoaqwcd paedtfphtz (asvmbfglfl, jasdiscvor - gmhxwfdxai)
View more
-
21 Feb 2021
(Group 2: cH8/1N1 LAIV and cH5/1N1 IIV)
zmechujyxm(tbhdaeirss) = mpnyzvsfii paedtfphtz (asvmbfglfl, vshgfmjbxj - lomaglvzpc)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free